Relmada Therapeutics and PyroGenesis Secure Capital Through Private Placements

Key Facts

1Relmada Therapeutics (RLMD) announced an oversubscribed $160.0 million private investment in public equity (PIPE) financing.

2Relmada's financing included participation from major institutions like Venrock Healthcare Capital Partners, Janus Henderson Investors, and RA Capital Management.

3PyroGenesis (PYR) announced its intention to complete a non-brokered private placement to raise up to $1,000,000 at $0.54 per unit.

Relmada Therapeutics (RLMD) has successfully announced an oversubscribed $160.0 million private investment in public equity (PIPE) financing. The financing round attracted significant interest from top-tier institutional investors, including Venrock Healthcare Capital Partners, Janus Henderson Investors, and RA Capital Management. These funds are earmarked to advance Relmada's clinical-stage therapies targeting oncology and central nervous system (CNS) indications. Simultaneously, PyroGenesis (PYR) disclosed its intention to complete a non-brokered private placement to raise up to $1,000,000. The PyroGenesis offering is priced at $0.54 per unit and aims to provide necessary liquidity for its plasma-based technology operations. The strong institutional backing for Relmada highlights market confidence in its development pipeline, while PyroGenesis secures capital for industrial growth.